Stem Cell Therapy: 5 Shocking Findings About iPSC Immune Rejection
Stem cell therapy has long been considered one of the most promising frontiers in regenerative medicine. The idea that cells derived from a patient’s own genetic material could be transplanted without triggering an immune response seemed logical — and for years, it was widely assumed to be true.
New research published in Cell Stem Cell challenges that assumption in ways that matter deeply for the future of stem cell therapy. The study, led by senior author Yang Xu, Ph.D., at UC San Diego, used humanized mouse models to demonstrate that not all cells derived from induced pluripotent stem cells (iPSCs) behave the same way in the immune system. Some are accepted. Some are rejected. And the reason why has significant implications for clinical research.
What Are iPSCs and Why Do They Matter for Stem Cell Therapy?
Induced pluripotent stem cells are adult cells that have been reprogrammed to behave like embryonic stem cells. This technology, developed by Kyoto University’s Shinya Yamanaka — who received the Nobel Prize in 2012 — was revolutionary because it offered a way to create powerful stem cells without using embryos.
The initial expectation was that iPSC derived cells would not trigger immune rejection when transplanted back into the patient from whom they were derived. This assumption made stem cell therapy using iPSCs appear inherently safe from an immunological standpoint.
However, a growing body of evidence has complicated that picture, and this study adds important new clarity.
5 Shocking Findings From This Stem Cell Therapy Immune Study
Finding 1: Not All iPSC-Derived Cells Behave the Same Way
The most striking finding of this stem cell therapy research is that two different cell types derived from the same iPSCs produced completely opposite immune responses. Retinal pigment epithelium (RPE) cells — the type found in the eye — were accepted by the immune system without triggering rejection. Smooth muscle cells (SMCs) derived from the same iPSC source were repeatedly rejected.
This finding overturns a foundational assumption in stem cell therapy research: that iPSC origin alone guarantees immune tolerance.
Finding 2: Immune Rejection in Stem Cell Therapy Is Linked to Abnormal Gene Expression
The research team analyzed why SMCs were rejected while RPE cells were not. They found that iPSC derived SMCs expressed different genes than normal SMCs and displayed significantly higher levels of immunogenic molecules — proteins capable of triggering an immune response. iPSC derived RPE cells, by contrast, showed low expression of the same immunogenic markers.
The underlying cause appears to be epigenetic abnormalities — non heritable changes in how genes are expressed — that occur during the iPSC reprogramming process. These abnormalities appear to affect different cell types in different ways, which explains why stem cell therapy outcomes may vary depending on what type of cell is being transplanted.
Finding 3: Eye Cells Enjoy a Natural Immune Advantage
One reason RPE cells may avoid rejection is that the eye is what researchers call an immune privileged site — an anatomical location where the immune system exerts less aggressive surveillance than in other tissues. When the same iPSC derived RPE cells were transplanted into skeletal muscle — a non privileged site — cells derived from normal human embryonic stem cells did trigger an immune response, while iPSC derived RPE cells still did not.
This distinction is critical for understanding where and how stem cell therapy can be safely applied in clinical settings.
Finding 4: A Single Protein Can Determine Whether Cells Are Rejected
To test their hypothesis about immunogenic proteins, the research team introduced a protein called Zg16 — one of the abnormally expressed markers found in iPSC derived SMCs — into iPSC derived RPE cells that had previously been immune tolerant. The result was unambiguous: those RPE cells were then rejected by the immune system.
This finding demonstrates that specific protein expression, not just cell origin, determines whether stem cell therapy triggers immune rejection. It also points toward a potential solution: if researchers can minimize the expression of these immunogenic proteins during the differentiation process, they may be able to reduce rejection risk significantly.
Finding 5: Clinical Trials With iPSC Derived Cells Must Account for Cell Type Specific Immunogenicity
Paul Knoepfler, Ph.D., an iPSC expert at UC San Diego who was not involved in the study, noted that the assumption that all iPSC derived cells can be given back to patients without immune concern “may not always be true” and should be actively considered as clinical research with iPSCs accelerates.
Joseph Wu, M.D., Ph.D., Director of the Stanford Cardiovascular Institute, agreed that future studies must focus on improving humanized mouse models to help design clinically applicable immunosuppression strategies for stem cell therapy — acknowledging that immune management will likely be necessary for some cell types even in autologous transplants.
What This Means for the Future of Stem Cell Therapy
This research does not diminish the promise of stem cell therapy. It sharpens it. By identifying the specific mechanisms that lead to immune rejection in some cell types but not others, researchers now have a clearer target for improving iPSC differentiation protocols and designing safer clinical applications.
Yang Xu and his team have stated that further work will focus on evaluating the immunogenicity of additional cell types derived from iPSCs, identifying approaches to minimize epigenetic abnormalities, and testing iPSC reprogramming methods that may produce less immunogenic cells across all tissue types.
For researchers and clinicians following this space, resources including the National Institutes of Health stem cell information portal and ClinicalTrials.gov provide current information on active stem cell therapy studies and regulatory developments.
Participate in Clinical Research With FOMAT Medical
At FOMAT Medical, we support Phase I through Phase IV clinical studies across multiple therapeutic areas throughout the United States. Research like this study on stem cell therapy immunogenicity represents exactly the kind of foundational science that our investigator network helps translate into real world patient benefit.
If you or someone you know may be interested in joining an active clinical study, explore our currently available trials.